

# inrals Intel - Focus on Brazil



## General situation in Brazil



**211**  
million

**Inhabitants**



**US \$ 6.783**

**Per capita GDP (2020)**

- ✓ Public debt: 98.94% of GDP (2020)
- ✓ Annual GDP Growth rate: 1.78% (2018), 1.41% (2019), -4,06% (2020)
- ✓ Unemployment rate: 13.5% (2020). Due to COVID-19

## Pharmaceutical and Life Science Industries in Brazil

- ✓ Brazil has the largest GDP in Latin America; is the 5th largest country in the world in terms of population and is the world's 7th largest pharmaceutical market.
- ✓ Total sales of drugs in the Brazilian market in 2020 amounted to USD 15.02 billion.
- ✓ Brazil's ranking in world markets is currently fluctuating between 6th and 7th place. At the current rate of growth, the country is expected to reach 5th place in 2023.
- ✓ In 2020, Brazil's drugs market consisted of 441 pharmaceutical companies (world rank 5th). Of these companies, 89 (20.18%) were international in origin and 352 (79.82%) owned by local investors.
- ✓ Brazil ranks 11th among the countries that have published most studies on COVID-19 since the pandemic began: 4,029 publications authored by researchers based in the country.



**At the start of 2020, the Brazilian pharmaceutical industry employed more than 90,000 people.**

## Promising market for clinical research



Brazil is 24th in the world ranking for clinical research, but proper exploitation of its potential could push it up to 10th, attracting an estimated investment of USD 386 million. The country's **biodiversity** - the world's largest - boosts its potential for inward investments. Action is taken to speed up approvals of Clinical Studies in Brazil. Today there are 4,935 clinical trials registered.

## Special features of the Brazilian market



By 2024, all the pharmaceutical products marketed in Brazil will be subject to a modern **tracking system** from the moment they leave the plant.



The National Health Surveillance Agency (ANVISA) is recognized as one of the world's best sanitary agencies. The entire population is guaranteed access to **healthcare** under the Brazilian Unified Health System (SUS). The periodical addition of modern drugs to the treatments offered by the SUS provides the population with the latest products and encourages laboratories to invest in innovation. Of 169 countries ranked for innovation, Brazil is number 66.



Of the 381 pharmaceutical laboratories in Brazil, 55% are located in the southeast region of the country. Companies based in the State of **São Paulo** employ 56% of the industry staff.

## INRALS Members



We are a consultancy business specialized in outsourcing professionals to the pharmaceutical segment.

Using our expertise, networking and strategic knowledge we provide our clients with the best talents to work on their projects - offering Outsourcing and Temporary Labor services.

Since over 20 years, we put our experience at the service of our customers and employees.

[www.captativa.com.br](http://www.captativa.com.br)



We are Life Recruiting, a boutique consultancy on recruitment of professionals for middle and top management positions for compa-

nies in the Healthcare industry, such as companies in the Pharmaceutical, Biotechnological, Hospital Medical Equipment, Dermocosmetics, CROs, Nutrition, Hospitals and Clinical Laboratory sectors. Life was born of the union of two senior professionals with more than 15 years of experience as headhunters. Two complementary points of view on how to deliver the best solutions for the particular demands of this market.

[www.liferecruiting.com.br](http://www.liferecruiting.com.br)